简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
Investors
（02186.HK）
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of：
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
2026
28
2026-08
Next Day Disclosure Return
27
2026-08
DISCLOSEABLE TRANSACTION FINANCE LEASE AGREEMENT
27
2026-08
ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026
26
2026-08
VOLUNTARY ANNOUNCEMENT CDE ACCEPTANCE OF IND APPLICATION FOR TL1A/IL-23 BISPECIFIC ANTIBODY BA2201
14
2026-08
VOLUNTARY ANNOUNCEMENT COMPLETION OF PHASE IA CLINICAL TRIAL OF BA1302 (CD228-DIRECTED ADC) IN CHINA
14
2026-08
INSIDE INFORMATION ANNOUNCEMENT PROFIT WARNING
14
2026-08
NOTICE OF BOARD MEETING
06
2026-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2026
05
2026-08
VOLUNTARY ANNOUNCEMENT BLA SUBMISSION FOR AFLIBERCEPT INTRAVITREOUS INJECTION IN BRAZIL
08
2026-07
VOLUNTARY ANNOUNCEMENT CDE ACCEPTANCE OF IND APPLICATION FOR BA1203 (A MASKED ANTI-PD-1/IL-2 FUSION PROTEIN)
1
2
3
4
5
Follow me
鲁公网安备37069102000284